(Abst.) Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center... on: June 09, 2026, 09:12:45 pm #1 From PubMed (June 9, 2026)--"Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis": Checking your browser - reCAPTCHA pubmed.ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
